Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility)

Irene J Higginson,1 Andrew Wilcock,2 Miriam J Johnson,3 Sabrina Bajwah,1 Natasha Lovell,1 Deokhee Yi,1 Simon P Hart,1 Vincent Crosby,5 Heather Poad,6 David Currow,7 Emma Best,6 Sarah Brown,6 on behalf of BETTER-B Feasibility Trial Group

ABSTRACT
New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ≥3. Sixty-four patients were randomised (409 screened), achieving our primary feasibility endpoint of recruitment. Most patients had COPD or interstitial lung disease; 52 (81%) completed the trial. There were no differences between placebo and mirtazapine in tolerability or safety, and blinding was maintained. Worst breathlessness ratings at day 28 (primary clinical activity endpoint) were 7.1 (SD 2.3, placebo) and 6.3 (SD 1.8, mirtazapine). A phase III trial of mirtazapine is indicated. Trial registration: ISRCTN 32236160; European Clinical Trials Database (EudraCT no: 2015-004064-11).

INTRODUCTION
Breathlessness is a prevalent and distressing symptom, associated with considerable disability, social isolation, emergency service use and poor survival.1 2 It often persists despite optimum pharmacological treatment of the underlying medical condition and non-drug approaches.1 3 4 Drug treatments are limited; opioids have the best evidence,5 6 but concerns remain regarding long-term effects. New treatments are required. Antidepressants impact on neurotransmitters involved in various brain circuits potentially affecting breathlessness, and are worthy of consideration.7 Data are mixed for selective serotonin reuptake inhibitors, with positive case series but a negative randomised controlled trial.8 9 Mirtazapine is an antagonist at α2-adrenergic, H1, 5HT2A/C and 5HT3 receptors, resulting in serotonin, norepinephrine and dopamine release.

Thus, we conducted a multicentre, randomised, placebo-controlled, double-blind, parallel-group, dose-escalating, mixed-methods, feasibility trial of mirtazapine for patients severely affected by breathlessness, to inform a potential phase III trial.

METHODS
For full details, see the Trial Protocol, online supplementary document S1.

Participants
Patients were recruited from three centres. Inclusion criteria were: consenting adults with a confirmed diagnosis (by hospitals/clinicians) of COPD, interstitial lung disease (ILD), cancer or chronic heart failure, plus clinician assessed modified medical research council (mMRC) breathlessness score of 3 or 4 despite optimal treatment of underlying disease(s) and prognosis of ≥2 months. Main exclusion criteria were: existing antidepressant use and contraindications to mirtazapine.

Trial design and procedures
Participants were randomised (1:1) to receive oral mirtazapine (15 mg/day (evening)) or placebo (capsules identical in appearance, smell and taste) for 28 days. Randomisation was stratified by disease (cancer vs non-cancer), Hospital Anxiety and Depression Scale (HADS) score (≥15 vs <15), and taking opioids (yes vs no).

The primary endpoint was number of patients recruited across three hospitals over 12 months, with a target of 60. Secondary endpoints, including proposed primary and secondary clinical activity outcomes for a main trial, are in online supplementary box S1. Assessments were at baseline and weekly thereafter, and included evaluation of breathlessness and related activity scales, toxicity, treatment adherence and quality of life. At 14 days, if the rating of worst breathlessness during the previous 24 hours had not improved ≥1 point on the 0–10 numerical rating scale (NRS) over baseline, the daily dose was increased to two capsules (placebo or 30 mg mirtazapine).

Semi-structured qualitative interviews with a purposive sample of participants, aiming to include a mix of diseases, experiences and backgrounds (subject to data saturation), explored motivations for trial participation and experiences of the intervention, procedures and study measures (see Trial Protocol, online supplementary document S1 page...
Figure 1 Consolidated Standards of Reporting Trials flow diagram of patients included in the trial, follow-up and analysis. #=reasons why seven patients were consented but not randomised were because they were found or became ineligible: started pulmonary rehabilitation (1); uncontrolled diabetes mellitus (2), started taking antidepressants (1), hepatic impairment (1), decided not on optimal treatment for underlying condition (1), and one missing. * Of those who discontinued intervention, patients were willing to continue data collection in all but one in the mirtazapine group and all but four in the placebo group, all available data were analysed.

Figure 2 Mean (95% CI) breathlessness at worst and average over 24 hours during the 28 days of the study, by study arm.

RESULTS

Recruitment and progress through trial

Each centre opened for 12 months; 409 patients were screened for eligibility and 64 randomised (16% of those screened; mean 5.3 per month) achieving the primary outcome of feasibility (figure 1). Most participants had COPD (64%) or ILD (31%), and mMRC grade 4 (58%); 33% were taking opioids and HADS score was ≥15 in 24 (38%). Demographics and clinical characteristics were balanced between randomised groups (online supplementary tables S1, S2).

Main reasons for ineligibility were existing antidepressant use (38%), mMRC score <3 (27%). Eighty-three (20% of 409 screened) patients declined participation. Reasons were mainly not liking the idea of a clinical (18%) or a blinded (7%) trial, not wanting to take additional medicine (18%), already having too much to think about (17%) and not liking the thought of
antidepressants (13%).

All randomised participants received at least one dose of mirtazapine or placebo, none were lost to follow-up (figure 1). Fifty-two participants (81%) remained on treatment all 28 days. Twenty-nine participants (45%) dose escalated at day 14; based on the same criteria at day 28, 21 participants (33%) would have been eligible for further dose escalation.

Twelve patients (six per arm) discontinued treatment prematurely. The Bang Blinding Index (BBI), which calculates differences between correct and incorrect guesses for unblinding (see online supplementary box S1), was 0.31 (95% CI 0.03 to 0.59) and 0.21 (95% CI −0.07 to 0.50) in the placebo and mirtazapine arms, respectively.

Toxicity and safety

There were few adverse events, with only one grade 3 reported (insomnia, day 28, placebo arm). There were 12 serious adverse events (SAEs) in nine participants (mean 1.3 per person, SD 0.71; mirtazapine: four people (seven events), placebo: five people (five events)). Only one SAE (a fall, with grade 2 dizziness and confusion) was assessed as being related to trial medication (placebo arm). Two patients died during the study, after 27 (mirtazapine) and 20 (placebo) days from baseline, both due to their underlying illness.

Other outcome data

There were little missing data (online supplementary table S3). At baseline, mean scores for worst breathlessness NRS were similar across treatment arms, with SD of 1.52 informing the phase III sample size calculation. Worst breathlessness improved similarly across treatment arms, with SD of 1.52 informing the decisions (placebo arm). Two patients died during the study, after 27 (mirtazapine) and 20 (placebo) days from baseline, both due to their underlying illness.

Table 1 Clinical activity outcomes and costs at day 28 of study by trial arm

<table>
<thead>
<tr>
<th>Clinical activity outcomes—mean (SD)</th>
<th>Mirtazapine n=30</th>
<th>Placebo n=34</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRS worst (last 24 hours)* day 28</td>
<td>6.3 (1.8)</td>
<td>7.1 (2.3)</td>
</tr>
<tr>
<td>change from baseline to day 28 mean (95% CI)</td>
<td>−1.3 (−2.1 to −0.5)</td>
<td>−0.8 (−1.6 to 0.0)</td>
</tr>
<tr>
<td>NRS average (last 24 hours)* day 28</td>
<td>4.7 (2.0)</td>
<td>4.9 (1.8)</td>
</tr>
<tr>
<td>change from baseline to day 28 mean (95% CI)</td>
<td>−0.7 (−1.2 to −0.2)</td>
<td>0.0 (−0.7 to 0.7)</td>
</tr>
<tr>
<td>IPOS total* day 28</td>
<td>17.2 (8.0)</td>
<td>17.8 (7.6)</td>
</tr>
<tr>
<td>HADS anxiety* day 28 [HADS depression* day 28]</td>
<td>4.3 (2.8) [6.1 (3.3)]</td>
<td>5.3 (3.5) [6.5 (3.7)]</td>
</tr>
<tr>
<td>SPPB†† day 28</td>
<td>7.6 (2.1)</td>
<td>7.4 (2.9)</td>
</tr>
<tr>
<td>CRQ dyspnea†§ day 28 [CRQ emotion†§ day 28]</td>
<td>3.1 (1.1) [5.0 (1.2)]</td>
<td>2.8 (1.0) [4.9 (1.3)]</td>
</tr>
<tr>
<td>CRQ fatigue†§ day 28 [CRQ mastery†§ day 28]</td>
<td>3.8 (1.3) [4.9 (1.2)]</td>
<td>4.0 (1.2) [4.9 (1.3)]</td>
</tr>
<tr>
<td>GSES total score† day 28</td>
<td>31.4 (5.1)</td>
<td>30.7 (4.8)</td>
</tr>
</tbody>
</table>

Economic measures—mean (SD)

| EQ-5D† day 28 | 0.61 (0.26) | 0.63 (0.15) |
| change from baseline to day 28 mean (95% CI) | 0.07 (0.00 to 0.15) | 0.03 (−0.04 to 0.09) |
| EQ-5D VAS† day 28 | 63.4 (21.2) | 60.8 (19.0) |

Health and social care costs (£) in the previous 1 month*

522 (773) 412 (529)

*Scale interpretation: high score worse.
†Scale interpretation: high score better.
‡Missing data were higher for SPPB than other measures (see online supplementary table S3)
§CRQ subdomains averaged on the 1–7 scale to give comparability across subscales.
¶Not all patients completed all five activity subscales. However, scores were similar, the data for those completing all five activity subscales are provided here.
CRQ, Chronic Respiratory Disease Questionnaire; EQ-5D, quality of life; GSES, General Self-Efficacy Scale; HADS, Hospital Anxiety and Depression Scale; HRQL, health-related quality of life; IPOS, Integrated Palliative care Outcome Scale; NRS, numerical rating scale; SPPB, Short Physical Performance Battery.

Qualitative data

Interviews were conducted with 22 participants (11 COPD, 8 I LD, 3 other) of whom two withdrew early because of adverse effects, see online supplementary box S2 for summary findings.

DISCUSSION

This feasibility trial successfully achieved its primary endpoint based on numbers recruited from three sites over 1 year, a pragmatic outcome based on completing a phase II study in a reasonable time. Uptake and data collection were high and attrition low for a population with advanced disease. Qualitative data suggest this is partly due to having dedicated research staff. The tolerability and safety of mirtazapine were good with little apparent loss of participant blinding (BBI close to zero in both arms). Our data have been used to inform development of an international multicentre phase III trial; this has secured funding.

Author affiliations

1 Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, Kings College London and King’s College Hospital NHS Foundation Trust, London, UK
2 Department of Clinical Oncology, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK
3 Wolfson Palliative Care Research Centre, Hull York Medical School, The University of Hull, Hull, UK
4 Respiratory Research Group, Hull York Medical School, University of Hull, Castle Hill Hospital, University of Hull, Hull, UK
5 Palliative Care, Nottingham University Hospitals NHS Trust, Nottingham, UK
6 Clinical Trials Research Unit (CTRU), University of Leeds, Leeds, UK
7 Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia

Acknowledgements

Trial Steering Committee (TSC) (also Data Monitoring and Ethics Committee) Members: We thank our independent TSC members for their wise advice and careful monitoring of the study. Dr Anthony Byrne (Chair) Cardiff and the Vale University Health Board. Dr Martin Denir (Cardiology Specialist) University of Edinburgh. Professor Marie Fallon (Palliative Care Specialist) University of Edinburgh. Dr Michael Peake (Respiratory Specialist) University Hospitals Leicester. Professor Julia Riley (Palliative Care Specialist) The Royal Marsden NHS Foundation Trust. Dr Sara Booth (Palliative Care Specialist)—University of Cambridge. Sharon Love


Table 1 Brief communication

(Statistician)—University of Oxford—Professor Trevor Sheldon (Health Services Research and Policy)—Non-independent member—University of York. Sylvia Bailey (Patient and Public Involvement Representative). We are grateful to our independent Patient and Public Involvement (PPI) team for their advice and support during the whole period of the study: Mandy Paine, Colleen Ewart, Gerry Bennison and Sylvia Bailey.

Collaborators We thank our collaborators for their help and advice during the project in particular: Dr Rohit Lal, Consultant Medical Oncologist; Dr Charles Reilly, Consultant Physiotherapist; Dr Matthew Maddocks, Senior Lecturer in Palliative care and Specialist Physiotherapist; Professor Surinder Birring, Professor of Respiratory Medicine; Dr Anna Gerratt, Dr Frank McCaughan, Dr Rachael Barton, Dr Irem Patel, Dr West, Wai Lam, Professor Charlotte Bolton, Dr William Chang, Professor Gisli Jenkins. Pharmacy (King’s College Hospital): Stuart Chandler and Research project co-ordinator Deborah Tonkin.


Funding We thank Marie Curie, Cicely Saunders International (CSI) and The Atlantic Philanthropies, Yorkshire Cancer Research whose funding made this study possible.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons/licenses/by/4.0/.

ORCID iDs
Irene J Higginson http://orcid.org/0000-0002-3687-1313
Andrew Wilcock http://orcid.org/0000-0002-3214-1188
Miriam J Johnson http://orcid.org/0000-0001-6204-9158
David Currow http://orcid.org/0000-0003-1988-1250

REFERENCES